LEADER 01225nam0 22003013i 450 001 VAN0274087 005 20240327113853.605 017 70$2N$a9783031374166 100 $a20240327d2023 |0itac50 ba 101 $aeng 102 $aCH 105 $a|||| ||||| 200 1 $aManual of Musculoskeletal Ultrasound$eA Self-Study, Protocol-Based Approach$fMark H. Greenberg, Alvin Lee Day, Suliman Alradawi 210 $aCham$cSpringer$d2023 215 $aXVII, 545 p.$d24 cm 620 $aCH$dCham$3VANL001889 700 1$aGreenberg$bMark H.$3VANV226449$00 701 1$aAlradawi$bSuliman$3VANV226451$01432792 701 1$aDay$bAlvin Lee$3VANV226450$01432791 712 $aSpringer $3VANV108073$4650 801 $aIT$bSOL$c20240614$gRICA 856 4 $uhttps://doi.org/10.1007/978-3-031-37416-6$zE-book - Accesso al full-text attraverso riconoscimento IP di Ateneo, proxy e/o Shibboleth 899 $aBIBLIOTECA CENTRO DI SERVIZIO SBA$2VAN15 912 $fN 912 $aVAN0274087 950 $aBIBLIOTECA CENTRO DI SERVIZIO SBA$d15CONS SBA EBOOK 12978 $e15EB 12978 20240327 996 $aManual of Musculoskeletal Ultrasound$93577820 997 $aUNICAMPANIA LEADER 02424nam0 22005893i 450 001 VAN00282671 005 20241213022356.934 017 70$2N$a9783030750855 100 $a20241107d2021 |0itac50 ba 101 $aeng 102 $aCH 105 $a|||| ||||| 181 $ai$b e 182 $ab 200 1 $aNuclear Security$eThe Nexus Among Science, Technology and Policy$fMichael Nacht, Michael Frank, Stanley Prussin 210 $aCham$cSpringer$d2021 215 $axvii, 340 p.$cill.$d24 cm 606 $a81V35$xNuclear physics [MSC 2020]$3VANC023270$2MF 606 $a91-XX$xGame theory, economics, finance, and other social and behavioral sciences [MSC 2020]$3VANC025601$2MF 610 $aArms control measures$9KW:K 610 $aAtomic energy commission$9KW:K 610 $aClimate change and nuclear war$9KW:K 610 $aClosed fuel cycle policy$9KW:K 610 $aNuclear Disarmament$9KW:K 610 $aNuclear Forensics$9KW:K 610 $aNuclear Proliferation$9KW:K 610 $aNuclear deterrence$9KW:K 610 $aNuclear detonation monitoring$9KW:K 610 $aNuclear enrichment$9KW:K 610 $aNuclear materials detection$9KW:K 610 $aNuclear security$9KW:K 610 $aNuclear stockpile stewardship$9KW:K 610 $aNuclear stockpile surveillance$9KW:K 610 $aNuclear weapons verification$9KW:K 610 $aPre- and post-detonation nuclear forensics$9KW:K 610 $aProliferation resistant policy$9KW:K 610 $aRadiation detection$9KW:K 610 $aRadiological terrorism$9KW:K 610 $aRegional proliferation$9KW:K 620 $aCH$dCham$3VANL001889 700 1$aNacht$bMichael$3VANV235576$01068758 701 1$aFrank$bMichael$3VANV235577$01767973 701 1$aPrussin$bStanley$3VANV235578$01767974 712 $aSpringer $3VANV108073$4650 801 $aIT$bSOL$c20241220$gRICA 856 4 $uhttp://doi.org/10.1007/978-3-030-75085-5$zE-book ? Accesso al full-text attraverso riconoscimento IP di Ateneo, proxy e/o Shibboleth 899 $aBIBLIOTECA DEL DIPARTIMENTO DI MATEMATICA E FISICA$1IT-CE0120$2VAN08 912 $fN 912 $aVAN00282671 950 $aBIBLIOTECA DEL DIPARTIMENTO DI MATEMATICA E FISICA$d08DLOAD e-Book 9641 $e08eMF9641 20241113 996 $aNuclear Security$94215537 997 $aUNICAMPANIA LEADER 04512nam 22006735 450 001 9910863153903321 005 20250325165636.0 010 $a9783030578145 010 $a3030578143 024 7 $a10.1007/978-3-030-57814-5 035 $a(CKB)4100000011569211 035 $a(DE-He213)978-3-030-57814-5 035 $a(MiAaPQ)EBC6387589 035 $a(PPN)252510240 035 $a(EXLCZ)994100000011569211 100 $a20201109d2020 u| 0 101 0 $aeng 135 $aurnn#008mamaa 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 14$aThe Science and Business of Drug Discovery $eDemystifying the Jargon /$fby Edward D. Zanders 205 $a2nd ed. 2020. 210 1$aCham :$cSpringer International Publishing :$cImprint: Springer,$d2020. 215 $a1 online resource (XVII, 402 p. 102 illus., 20 illus. in color.) 311 08$a9783030578138 311 08$a3030578135 320 $aIncludes bibliographical references and index. 327 $aIntroduction -- PART 1: How Drugs are Discovered and Developed in the Pharmaceutical Industry -- Introduction to Drugs and Drug Targets -- Background to chemistry of small and large molecules -- Laying the foundations- Drug discovery from antiquity to the twenty first century -- Part II-The drug development pipeline ? discovery to testing in humans -- Drug discovery pipeline overview -- Target discovery -- Medicinal chemistry -- Biotherapeutics -- Screening for hits -- Process chemistry and formulation -- Preclinical development -- Part III-The drug development pipeline ? clinical trials to marketing authorisation -- Clinical trials -- Regulatory affairs and marketing approval -- Diagnostics and personalized medicine -- Putting it All Together: a drug development case history -- Part IV- The Global Pharmaceuticals Business -- Commercial aspects of drug development -- Challenges and responses -- Part V - Professional Interactions with the Drug Discovery Industry.-Professional Interactions with the Drug Discovery Industry: Technology Transfer Executives -- Recruitment Executives -- Pharmaceutical translators and Interpreters. 330 $aThe Science and Business of Drug Discovery is written for those who want to learn about the biopharmaceutical industry and its products whatever their level of technical knowledge. Its aim is to demystify the jargon used in drug development, but in a way that avoids over simplification and the resulting loss of key information. Each of the twenty chapters is illustrated with figures and tables which clarify some of the more technical points being made. Also included is a drug discovery case history which draws the relevant material together into a single chapter. In recognizing that it is difficult to navigate through the many external resources dealing with drug development, the book has been written to guide the reader towards the most appropriate information sources, including those listed in the two appendices. The following topics are covered: Different types of drugs: from small molecules to stem cells Background to chemistry ofsmall and large molecules Historical background to drug discovery, pharmacology and biotechnology The drug discovery pipeline: from target discovery to marketed medicine Commercial aspects of drug discovery Challenges to the biopharmaceutical industry and its responses Material of specific interest to technology transfer executives, recruiters and pharmaceutical translators . 606 $aPharmacology 606 $aPharmacovigilance 606 $aPharmaceutical chemistry 606 $aChemistry, Physical and theoretical 606 $aBiotechnology 606 $aPharmacology 606 $aDrug Safety and Pharmacovigilance 606 $aPharmaceutics 606 $aTheoretical Chemistry 606 $aBiotechnology 615 0$aPharmacology. 615 0$aPharmacovigilance. 615 0$aPharmaceutical chemistry. 615 0$aChemistry, Physical and theoretical. 615 0$aBiotechnology. 615 14$aPharmacology. 615 24$aDrug Safety and Pharmacovigilance. 615 24$aPharmaceutics. 615 24$aTheoretical Chemistry. 615 24$aBiotechnology. 676 $a615.19 700 $aZanders$b Edward D.$0511858 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910863153903321 996 $aThe science and business of drug discovery$93562757 997 $aUNINA